Corvus Pharmaceuticals (CRVS) Equity Ratio (2016 - 2026)
Corvus Pharmaceuticals' Equity Ratio history spans 12 years, with the latest figure at 0.95 for Q1 2026.
- Quarterly Equity Ratio rose 14.55% to 0.95 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.95 through Mar 2026, up 14.55% year-over-year, with the annual reading at 0.86 for FY2025, 82.08% up from the prior year.
- Equity Ratio came in at 0.95 for Q1 2026, up from 0.86 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.95 in Q1 2026 to a low of 0.21 in Q3 2024.
- The 5-year median for Equity Ratio is 0.85 (2023), against an average of 0.79.
- Year-over-year, Equity Ratio tumbled 75.26% in 2024 and then surged 322.69% in 2025.
- Corvus Pharmaceuticals' Equity Ratio stood at 0.82 in 2022, then increased by 3.27% to 0.85 in 2023, then plummeted by 44.34% to 0.47 in 2024, then soared by 82.08% to 0.86 in 2025, then increased by 10.45% to 0.95 in 2026.
- Per Business Quant, the three most recent readings for CRVS's Equity Ratio are 0.95 (Q1 2026), 0.86 (Q4 2025), and 0.89 (Q3 2025).